Everything below concerns clinical development. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-07-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
Apart from negative affectivity and disinhibition, research has found "substantial but mixed" associations with the other trait domains, indicating the heterogeneity of the diagnosis, which aligns with the view of BPD as an "index of global personality pathology and severity, which aligns with the original metaphorical use of the term 'borderline' or 'borderland'". It is suggested that it "therefore seems reasonable if the borderline pattern serves as a transitional specifier that eventually is phased out in the coming era".
After the defeat of Prussia by Napoleon and the subsequent reorganisation of the Prussian state, the academy was merged on 3 August 1811 with the Protestant Viadrina University, previously located in Frankfurt (Oder), and re-established in Breslau as the Königliche Universität zu Breslau – Universitas litterarum Vratislaviensis (in 1911 named the Schlesische Friedrich-Wilhelms-Universität zu Breslau, to honour the founder Frederick William III of Prussia). At first, the conjoint academy had five faculties: philosophy, medicine, law, Protestant theology, and Catholic theology. Connected with the university were three theological seminars, a philological seminar, a seminar for German Philology, another seminar for Romanic and English philology, an historical seminar, a mathematical-physical one, a legal state seminar, and a scientific seminar. From 1842, the university also had a chair of Slavic Studies. The university had twelve different scientific institutes, six clinical centers, and three collections. An agricultural institute with ten teachers and forty-four students, comprising a chemical veterinary institute, a veterinary institute, and a technological institute, was added to the university in 1881. In 1884, the university had 1,481 students in attendance, with a faculty numbering 131.
Although not yet proven, these effects suggest that it is possible to activate PI3K/Akt/GSK3B/Fyn dependent signaling pathways through cardiac MT overexpression to prevent chronic IH-induced cardiomyopathy and downregulation of Nrf2. Therefore, Nrf2 or MT may be a potential treatment to avoid chronic IH-induced cardiomyopathy.
A third ZIPRA incursion attempt in July 1969 met with similarly catastrophic results. Thereafter, ZIPRA abandoned the notion of attempting to infiltrate the country with large groups of insurgents equipped only with small arms; it limited itself to more irregular forms of warfare until it could stockpile enough heavy weaponry to mount a major conventional invasion. For its part, the ZANLA leadership criticised ZIPRA's continued fixation with winning a major conventional engagement, arguing that the failed incursions demonstrated the futility of engaging the Rhodesian military in the type of pitched battles in which it held an indisputable advantage. ZIPRA's failure to obtain support from the locals was also noted, and ZANLA began implementing a long-term covert politicisation programme to cultivate civilian support throughout its future area of operations.
Histiocytic diseases in dogs are a group of diseases in dogs which may involve the skin, and which can be difficult to differentiate from granulomatous, reactive inflammatory or lymphoproliferative diseases. The clinical presentation and behaviour as well as response to therapy vary greatly among the syndromes. There are at least four well-defined canine histiocytic diseases:
Sources: en.wikipedia.org
==== Australia ==== In Australia, LSD is classified as a Schedule 9 prohibited substance under the Poisons Standard (February 2017), indicating it may be abused or misused and its manufacture, possession, sale, or use should be prohibited except for approved research purposes. In Western Australia, the Misuse of Drugs Act 1981 provides guidelines for possession and trafficking of substances like LSD.
Spelling conventions vary between regions. For example, current North American and international usage favors estrogen and gonadotropin, whereas British usage retains the Greek digraph in oestrogen and prefers the earlier spelling gonadotrophin. The following is a list of hormones found in Homo sapiens organized by structural classes.
=== Abuse === In 1924, the United States banned the sale and importation of opium for the manufacture of heroin, an opioid pain medication which was being abused. See Anti-Heroin Act of 1924. Beginning in the 1990s, prescription opioid drug abuse has been a prevalent public health issue of concern. Since 2013, with greatly increasing morbidity and deaths from overdoses of synthetic opioids, such as oxycodone, tramadol, and fentanyl, this issue has developed into a full-fledged epidemic. This has led to several other public health issues, including the spread of diseases like hepatitis C and human immunodeficiency virus (HIV). In the United States, as of 2013 more than 12 million people abused opioid drugs at least once a year. In 2010, 16,652 deaths were related to opiate overdose, in 2015 this number increased to 33,091. In September 2013, new FDA labeling guidelines for long-acting and extended-release opioids required manufacturers to remove moderate pain as use indication, reserving the drug for "pain severe enough to require daily, around-the-clock, long-term opioid treatment" however it did not restrict physicians from prescribing opioids for moderate, "as needed" usage. In January 2013, the Centers for Disease Control and Prevention (CDC) reported an illness associated with intravenous (IV) abuse of oral Opana ER (oxymorphone) in Tennessee. The syndrome resembled that of thrombotic thrombocytopenic purpura (TTP). Initial therapy included therapeutic plasma exchange, as for TTP.
=== Fluorescence of recombinant resilin === One unique property of rec1-Resilin is its ability to be identified due to autofluorescence. Fluorescence for resilin stems primarily from dityrosine, which are the result of crosslinks of tyrosine residues. When ultraviolet light irradiates a sample of rec1-Resilin at 315 nm to 409 nm emissions, the rec1-Resilin begins to show blue fluorescence. An example of the blue fluorescence exhibited by the dityrosine residues in resilin is shown in the figure below of a flea.
Sources: en.wikipedia.org
== Synthesis == Calcination of lanthanum(III) sulfate in oxygen current at 750 °C: La2(SO4)3 + O2 → La2O3·SO3 + 2SO3 The resulting product is reduced with hydrogen when heated: La2O3·SO3 + 4H2 → La2O2S + 4H2O
=== Venezuela === On 18 August 2025, Maduro said the US "has gone mad and has renewed its threats to Venezuela's peace and tranquility" and "announced the planned deployment of more than 4.5 million militia members" around Venezuela. The Economist was skeptical of the announcement, stating, "Election receipts show he received fewer than 3.8m votes last year; it is improbable that more people would fight to defend him than would vote for him." The International Institute for Strategic Studies estimated the militia had 343,000 members as of 2020. The BBC reported that many of the recently mobilized militia are "mostly made up of volunteers from poor communities, although public sector workers have reported being pressured into joining them as well." On 25 August, Maduro "said 15,000 'well armed and trained' men had been deployed to states near the Colombian border," per The Economist.
=== Limitation of structure databases === Structure databases are orders of magnitude larger than spectral libraries but still incomplete. It is understood that not every existing biomolecule is or will be contained in structure databases. For these instances, SIRIUS offers several solutions:
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.